Drug intelligence / Profile preview

HEC-C046

Development stage: Preclinical
Lead developer: Dongguan HEC Biopharmaceutical
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous Injection

Overview

HEC-C046 is a dual receptor agonist targeting both **Glucagon-like peptide 1 receptor (GLP-1R)** and **Glucagon receptor (GCGR)**. It is used for its potential in treating obesity and metabolic diseases by improving glycemic control and weight loss. The drug is developed using Fc fusion protein technology and has shown efficacy in diet-induced obese (DIO) and ob/ob mice models[1][2][3].

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on HEC-C046.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC-C046.

Explore the full profile